



## **TARPSWG Semi-Annual Meeting, Vancouver**

**Wednesday Nov 16, 2022, 8am-12pm.**

### **MEETING MINUTES**

**Attendees:** Markus Albertsmeier, Christina Angeles, Noemi Arrighetti, Yolanda Augustin, Yael Babichev, Jyoti Bajpai, Giacomo Giulio Baldi, Marc Bemelmans, Alexia Bertuzzi, Andrew Bishop, Sylvie Bonvalot, Dario Callegaro, Ken Cardona, Claudia Hayde Caro Sanchez, Denise Caruso, Charles Catton, Tom Wei-Wu Chen, Peter Chung, David Coker, Sara Coppola, Andrea Covelli, Anna Czarwecka, Lorenzo D'Ambrosio, Maria Danieli, Angelo P. Dei Tos, Nicolas Devaud, Palma Dileo, Ashley Drohan, Sanne Engelen, Chiara Fabbroni, Jeffrey Farma, Marco Fiore, Samuel Ford, Dorian Yarih Garcia Ortega, Maikim Gervais, Claudia Giani, Rebecca Gladly, Valerie Grignol, Peter Grimison, Alessandro Gronchi, David Gyorki, Rick Haas, Trevor Hamilton, Andrew Hayes, Angela Hong, Paul Huang, Tom Imai, Alexandra Istl, Robin Jones, Bernd Kasper, Moritz Kath, Emily Keung, Kristien Keymeulen, David Guy Kirsch, Nicole Larrier, Herbert Loong, Andrea MacNeill, Joshua Mammen, Gary Mann, Karla Martin Tellez, Martin McCarter, Christian Meyer, Aisha Miah, John Mullinax, Andrea Napolitano, Johanna Nin, Emanuela Palmerini, Sandro Pasquali, Elisabetta Pennacchioli, Chandrajit Raut, Mauricio Fernando Ribeiro, Christina Roland, Daniela Salvatore, Laura Samà, Roberta Sanfilippo, Catherine Sarre, Marta Sbaraglia, Astrid Scholten, Luke Selby, Joel Shapiro, Tatsumori Shimo, Jason Sicklick, Paweł Sobczuk, Silvia Stacchiotti, Madeleine Strach, Dirk Strauss, Joanna Szkandera, Charles Theuer, Fabio Tirota, Thui Tran, William Tseng, Claudia Valverde, Frits Van Coevorden, Winette Van der Graaf, Winan Van Houdt, Astrid Vernemmen, Rachel Voss, Micheal Wagner, Francis Zih

**Online Attendees:** Dagmar Adamkova Krakorova, José Manuel Asencio, Luo Cheng Hua, Carlo Maria Cicala, Sinziana Dumitra, Andrea Espejo Freire, Ferran Ferragut, Jens Jakob, Wendy Johnston, Miranda Lam, Katie Lee, Danielle Maes, Francisca Neemann, Leandro Nikisch, Marko Novak, Sergio Damián Quilidrian, Raza Sayyed, Sergio Valeri, Ann Valter, Conception Victoria

**Apologizes:** Samuel Aguiar, Nita Ahuja, Albina Allajbej, Elizabeth Baldini, Sebastian Bauer, Chiara Colombo, Aimee M Crago, Mark Fairweather, Peter Hohenberger, Daphne Hompes, Shintaro Iwata, Alex Kalinin, Roberta Maestro, Federico Navarra, Carolyn Nessim, Maxim Nikulin, Bibiana Purgina, Paul Ridgway, José Fernando Robles Díaz, Piotr Rutkowski, Kilian Salerno, Rupen Shah, Mateusz Spalek, Carol Swallow, Anastasia Tararykova, Tatiana Titova, Gabrielle H. van Ramshorst

**\*\* Slides Presentation are available for members on TARPSWG website at this link:**

**<https://tarpswg.org/ctos-2002-semiannual-meeting-presentation-slides/> \*\***

### **1. Welcome and Introduction of New members – A. Gronchi – R. Gladly (10 mins)**

New members attending the meeting are welcomed: 4 Surgeons, 1 Pathologist, 1 Medical Oncologist

### **2. STRASS 2 update – W. vanHoudt (35 mins)**

a. Update on accrual and site activation Europe– W. van Houdt (5 minutes).

b. Update on accrual Internationally – R. Gladly (Canada), S. Iwata (Japan), K. Cardona (USA), D. Gyorki (Australia) – (10 mins)

An update of the activation of protocol is given: all sites in Europe are activated, however not all sites recruiting yet; Canadian centers are recruiting; ANZA centers are also recruiting; US and Japan are still in the process to activate.

Some concern on recruitment rate, lower than predicted —but this is expected according to delays in activation process and intercurrent pandemic. Recent accrual trend is favourable.

c. STRASS 2 - Substudies discussion – D. Gyorki (10 mins)

i. Patients preference substudy: to understand how patients consider the relative benefits and harms of (neoadjuvant) chemotherapy

ii. PET substudy: Hypothesis is that early on-treatment PET (post-cycle 1) will identify patients for whom further systemic therapy is futile. This substudy is not aimed to change physician's choice about treatment, but to collect evidence for future application of PET. (Concern in the US to get the second PET if not approved by insurance)

d. EU grant application for STREXIT2 W. vanHoudt (10 mins)

Grant submitted for funding (Horizon-Miss-2022-CANCER-01-03): awaiting for response

### **3. Clinical Trial Committee – C. Roland (35 mins)**

a. New concepts introduction –

i. The use of TXA in Retroperitoneal Sarcoma surgery – C. Roland (10 mins)

Eight TARPSWG centers routinely using TXA for bleeding prophylaxis based on published data in fields of abdominal surgery. TXA approved in NICE guidelines in UK.

Due to recent data, the plan is to move away from this being a trial in RPS, though to consider a Subgroup Committee to look at this further. Role of bleeding among risk prediction in RPS patient may be also explored within the Complexity Score project.

ii. Short course XRT in RP sarcoma – C. Raut (10 mins)

Study proposal to determine the maximum tolerated dose (MTD) of hypofractionated radiotherapy for primary and recurrent RPS using increasing dose per fraction and based on acute toxicity.

Comments: global interest on the topic, though concern for surgical toxicity after hypofractionated therapy to a large field. Rick Haas volunteered to help in design the study.

b. Prospective observational study on preop RT in first recurrent retroperitoneal liposarcoma – A. Hong (15 mins)

Study outline circulated among members in last 2 years, now a complete study draft is almost complete: Prospective study evaluating the treatment outcomes for localised recurrent, resectable retroperitoneal liposarcoma (**ReLaPSe**)

Two non-randomized study groups: Group 1 – Surgery with preop RT; Group 2 – Surgery without preop RT; 100 patients expected, minimum 40 patients per Group, over 3 yrs.

Primary objective: Abdominopelvic recurrence-free survival (ARFS) from the date of treatment to the date of radiological abdominopelvic relapse or death

Comments: moving this concept forward early next year; Redcap platform (Sam Ford will help); Rick Haas brought up the possibility of QA of radiation therapy delivery

4. Translational Research Committee – R. Gladdy (30 mins)

a. Translational Studies from Clinical Trials committee (recurrent LPS) – R. Gladdy (10mins)

Opportunities to explore “unanswered questions” in regards to LPS pts undergoing radiation therapy: Emily Keung presented the need for tissue biopsy to conduct such studies

b. Biofilm concept presentation—C. Raut (10min)

Drug-Eluting Polymer Films to be positioned in the surgical tumor bed.

Summary of a decade worth of work evaluating this platform (paclitaxel and more recently doxorubicin-based films); promising animal model data; their model such canine model discussed—financial restrictions

c. Cellular therapy in STS- J. Mullinax (10min)

Elegant data on adoptive T cell therapy in STS. Combined experimental data with ORION database (WGS data). Trm (resident memory) focused

BREAK 15 mins

5. RESAR update - M. Fiore (25 mins)

a. Update on Contracts and IT for Centralization – M. Fiore (15 mins)

b. Update on future RESAR studies – Marco Fiore (5mins)

Complexity score dataset ready for last data-cleaning and analysis by Mark Fairweather (1294 pts from 22 centers)

Ongoing progress on data transfer agreement through the Emended Framework Agreement and DUF signature for the 5 ongoing RESAR studies amongst participating centers

Urgent need to receive comments on emended contract by the 12 partners within end of November – last deadline for local Legal Offices.

Recruitment: 2951 patients in 44 active sites; 11 sites with ongoing activating process; 31 other centers expressed initial interest but no feedback after that

Centralization testing undergoing through email contact with BBS company

For info and support: [daniela.salvatore@istitutotumori.mi.it](mailto:daniela.salvatore@istitutotumori.mi.it)

c. Pathology manuscript update – B. Purgina (5 mins)

A manuscript on Guidelines for pathological sampling and report is in development by a dedicated Taskforce after a comprehensive review of pathological item collected/to be collected in RESAR—any further input welcome

6. SARveillance update – S. Ford (15 mins)

a. Update on Status of the RCT – S. Ford (5 mins)

A study protocol is under preparation, this will move ahead as the first registry trial for RESAR  
Expected 600 pt in the trial

QoL component (which is primary endpoint) needs to be incorporated into RESAR agreement.

b. Presentation of Surveillance Retrospective study – D. Maes (10 mins)

Study approved by REC and open to any TARPSWG center for participation

It will capture both data within RESAR timeframe but also before 2017

Presently, in the process of DUA development

All members are invited in the meantime to complete this survey:

<https://bham.onlinesurveys.ac.uk/surveillance-rps> (or scan QR)

Password: TARPSWG2022



7. TARPSWG Incubator Session (C. Raut, K. Cardona, D. Gyorki) – (20 mins)

a. Introduction of new concept of Incubator Sessions at the Semi-Annual Meetings – K. Cardona (10 mins)

Incubator session has been proposed to critically review study proposals during Semiannual Meeting, in order to stimulate discussion, improve efficacy of study planning and mentor young members in the process.

b. Presentation of Vascular Resection study for Feedback – F. Tirotta (10 mins)

Methods: RPS with vascular resection between 2010-2021; Primary outcomes: 1- and 2-year patency rate; 90-day morbidity mortality

Comments: concern for ability to truly identify patency of graft; is graft patency endpoint the best endpoint?; morbidity should be adapted – whether related to vascular procedure or not; consider patient with no vascular reconstruction after venous resection (not evaluable for primary outcome!)

8. REC Committee update – (30 mins)

a. Update on REC Proposal Guidelines – C. Nessim (10 mins)

New guidelines will be proposed in order to improve efficacy of the process of new study proposal, and mostly to improve the timely completion of approved studies. This is briefly presented at the meeting in the interest of time. Full documents is attached to the minutes for members consideration

b. Inguinal sarcoma presentation – refresh and update —Jeff Farma (10 mins)

Initial study concept has been finalized and moving ahead: new definition of “anatomic” inclusion criteria.

Centers who already expressed interest in the study will be contacted to confirm; new centers interested in participating should contact [Jeffrey.Farma@fccc.edu](mailto:Jeffrey.Farma@fccc.edu)

c. Structured Reporting in RPS Imaging – Markus Albertsmeier (10 mins)

Comprehensive proposal to structure radiologic reporting and classification through radiomics tools; an online platform would help in collect and analyse data. Potentially to be integrated in RESAR for the future.

Project is moving ahead; looking for funding in the meantime.

A pilot study is presently ongoing involving LMU Munich, Royal Marsden Hospital, University of Mannheim.

d. Transferability of cancer registry data to clinical practice in RPS – Jens Jakob (5 mins)

Hypothesis generating proposal to compare outcome in patients recorded in German cancer registries with outcome in 1007 pts TARPSWG series

e. DSRCT project update – Sophie Rejiers (5 mins)

Update of the project, a comprehensive platform for data capture has been built in CASTOR. Ongoing DUA preparation. Other project/study on DSRCT would be welcome and could be integrated in the platform.

9. Education Committee/Webinar Series update – D. Callegaro/J Farma (10 mins)

a. Webinars for 2023

Registration to webinars had a great impact from CTOS mailing list and ESSO advertising. Successful initiatives, available on demand through YouTube channel also after event (please refer to <https://tarpswg.org/webinars/>)

The group is thinking ahead at what will be the next educational series after the topic of RPS will be probably exhausted.

10. International Tumour Board update – J. Sicklick (10 mins)

Origin of this endeavor started from the uncertainty of defining “resectability”

17 virtual tumor board already occurred; median 20 participants from 15 countries; 80% prospective cases presented; 55% cases presented are LPS. Importantly, a change in treatment plan occurred in 1/3 of prospective cases.

Comments: to increase wider participation consider endorsement by SSO/ESSO; consider diverse day/time schedule; proactive involvement of local RESAR PIs in presenting cases.

11. Closing remarks and group photo – A. Gronchi (5 mins)

Announcement of an upcoming educational surgical video series promoted with support from Annals of Surgical Oncology. Members are invited to be prepared to contribute video of RPS surgical procedures in coming months.

The traditional group picture is taken and attached to minutes documentation.

---

The meeting is adjourned, save the date for next Semiannual Meeting to be held in person on

**Wednesday March 22<sup>nd</sup> in Boston** during SSO2023

We thanks Dr. Chandrajit Raut for being our local host for next meeting.